Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02212574 · ClinicalTrials.gov registry record · Early Phase 1
Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
A Early Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT02212574 is a Early Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 6 participants.
The verdict
NCT02212574, a Early Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Participants enrolling on this study will receive standard of care chemotherapy for Wnt positive medulloblastoma without the radiation therapy or the weekly chemotherapy that is given during radiation therapy.
Interventions
- DRUG Cyclophosphamide
- DRUG Cisplatin
- DRUG Mesna
- DRUG Vincristine
- DRUG Lomustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-04-04 |
| Est. Completion | 2018-11-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02212574
The ClinicalTrials.gov registry entry for NCT02212574 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02212574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02212574 about?
NCT02212574 is a clinical study titled "Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma". Participants enrolling on this study will receive standard of care chemotherapy for Wnt positive medulloblastoma without the radiation therapy or the weekly chemotherapy that is given during radiation therapy.
What is the current status of trial NCT02212574?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2017-04-04. Estimated completion is 2018-11-09.
What interventions are being tested in trial NCT02212574?
The interventions under investigation include: Cyclophosphamide (DRUG), Cisplatin (DRUG), Mesna (DRUG), Vincristine (DRUG), Lomustine (DRUG).
Who is sponsoring clinical trial NCT02212574?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.